Panelists discuss how primary care awareness of biologics and Janus kinase (JAK) inhibitors for atopic dermatitis (AD) remain limited, with outreach efforts by dermatology groups and industry partners showing mixed success in education. While patients on biologics generally report significant symptom improvement, measured through validated tools like EASI, SCORAD, and patient-reported outcome measures, ongoing efforts are needed to bridge the knowledge gap in primary care settings.
Panelists discuss how the emergence of targeted biologics has revolutionized atopic dermatitis treatment by offering effective alternatives to traditional therapies. These agents, including IL-4/IL-13 inhibitors like dupilumab and others targeting specific inflammatory pathways, have provided new options for moderate to severe cases resistant to conventional treatments.
Panelists discuss how upcoming topical therapeutics for atopic dermatitis include corticosteroid-sparing treatments like topical calcineurin inhibitors (eg, tacrolimus, pimecrolimus), Janus kinase (JAK) inhibitors (eg, ruxolitinib), and phosphodiesterase-4 inhibitors (eg, crisaborole) for effective symptom management.
Panelists discuss how primary care physicians often serve as the first point of contact for patients with atopic dermatitis symptoms. Dermatologist referral is typically considered when patients show severe or persistent symptoms despite initial treatment, have unclear diagnosis, require specialized therapies, or experience significant impact on quality of life.
Panelists discuss how atopic dermatitis severity classification relies on multiple assessment tools including EASI, SCORAD, POEM, and BSA measurements. Special attention is given to sensitive areas (hands, feet, genitals) as they significantly impact quality of life. Disease extent, intensity of symptoms, and functional impairment guide categorization into mild, moderate, or severe cases.
In this episode, James Q. Del Rosso, DO, joins The Medical Sisterhood for a conversation about empowerment and the benefits of female role models.
Panelists discuss how they assess atopic dermatitis across all age groups by evaluating clinical history, symptom severity, and physical examination. They consider factors like age-specific presentations, comorbid conditions, and response to treatment for individualized management.
Panelists discuss how adult atopic dermatitis diagnosis relies on clinical presentation of chronic, pruritic, and eczematous lesions with characteristic distribution patterns. Unlike children, adults show more lichenified plaques and predominant hand/foot involvement. Key diagnostic criteria include personal/family history of atopy and chronic/relapsing course. No definitive test exists.
Shadi Kourosh, MD, MPH, joins The Medical Sisterhood to discuss advocacy, mentorship, and the empowerment of women in medicine.
Susan Taylor, MD, and Linda Stein Gold, MD, join The Medical Sisterhood for an intimate conversation on the importance of role models and mentors.
Alexandra Golant, MD, joins the program for a deep dive into her experience with motherhood, striking an optimal balance between her career and her personal life, and more!
In this episode, Tina Bhutani, MD, MAS, joins The Medical Sisterhood for a discussion about confronting imposter syndrome as a woman in medicine.
The Medical Sisterhood, hosted by Mona Shahriari, MD, is the latest multimedia program from HCPLive Dermatology!
Experts conclude the series discussing how to approach switching psoriasis treatments.
Experts discuss package warnings associated with bimekizumab and how they inform patients of them.
Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments.
Experts discuss the warnings regarding IL-17 blockers and inflammatory bowel disease.
Experts emphasize the importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.
Experts highlight how a history of cancer may impact psoriasis treatment decisions while touching on the safety profiles of newer IL agents.
Experts discuss common comorbidities for patients with plaque psoriasis and how they can impact treatment decisions.
Experts discuss the landscape of IL therapies for the treatment of psoriasis, highlighting their improved safety and efficacy over prior agents.
Experts discuss the use of TNF blockers in treating plaque psoriasis and their limited but important uses today.
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share advice for improving psoriasis care for patients with skin of color.
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai share how they utilize biologics data from skin of color cohorts in their practice.
Drs Stein Gold and Desai share their thoughts on the early use of psoriasis systemic treatments in patients with skin of color.
Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.
Dermatology experts highlight VISIBLE trial results when using guselkumab in patients with skin of color.
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai discuss VISIBLE trial, a randomized clinical trial specifically designed to examine treatment outcomes with guselkumab in patients with skin of color.
Drs Desai, Shahriari, and Stein Gold examine use and place of traditional systemic treatments in psoriasis.
Dr Stein Gold and Dr Shahriari review steroidal and non-steroidal topical treatments that are available for use in psoriasis.
